About BioCryst Pharmaceuticals, Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703
BioCryst Pharmaceuticals, Inc News and around…
Latest news about BioCryst Pharmaceuticals, Inc (BCRX) common stock and company :
BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 24, BioCryst Pharmaceuticals Inc's Director, Vincent Milano, invested $91,425.00 into 7,500 shares of BCRX, for a cost per share of $12.19..
Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.
Investors who take an interest in BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) should definitely note that the Senior...
Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich.
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH). REDEEM-2 is a randomized, placebo-controlled trial evaluating the efficacy and safety of BCX9930 (500 mg bid) as monotherapy versus placebo in approximately 57 PNH patients not currently receiving compleme
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...
A drugmaker headquartered in Durham announced deals totaling $350 million that will support its product development and commercial operations.
Royalty Pharma plc(NASDAQ: RPRX) andOMERS Capital Marketshave announced transactions worth$350 million in new ...
Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closi
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK, RESEARCH TRIANGLE PARK, N.C. and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and OMERS Capital Markets (OMERS), today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately ava
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here are seven top growth stocks investors may want to consider when looking at options in this hyper-growth market right now. The post 7 Top Growth Stocks to Buy as We Step Into November appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
Biocryst Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic therapiesRESEARCH TRIANGLE PARK, N.C., Nov. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from studies evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE), including results showing sustained reduction of HAE attack rat
It has been no fun being a BioCryst (BCRX) Investor this week; the market appeared unsatisfied with the biotech’s Q3 earnings and over the past two sessions has sent shares down by 24%. In the quarter, revenue dropped by ~18% sequentially (due to a Q2 one-off payment), although the top-line figure came in at $41 million, just ahead of the consensus estimate of $40 million. Most of the company’s revenue is derived from Orladeyo, BioCryst’s oral treatment for the prevention of hereditary angioedem
Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ontrak Inc (OTRK), where a total of 6,061 contracts have traded so far, representing approximately 606,100 underlying shares. That amounts to about 179.4% of OTRK's average daily trading volume over the past month of 337,780 shares..
BCRX earnings call for the period ending September 30, 2021.
In trading on Wednesday, shares of BioCryst Pharmaceuticals Inc (BCRX) crossed below their 200 day moving average of $13.72, changing hands as low as $12.75 per share. BioCryst Pharmaceuticals Inc shares are currently trading down about 15.7% on the day..
The biotech's third quarter was a good one, once you look past the top-line numbers.
Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular ...
BioCryst (BCRX) delivered earnings and revenue surprises of -10.00% and 8.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market ...
—3Q 2021 revenue of $41.0 million— —ORLADEYO® (berotralstat) net revenue of $37.0 million— —Full year 2021 ORLADEYO net revenue expected to be $115-$120 million— RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2021, and provided a corporate update. “With the significant revenue of $115 million to $120 million we expect to generate with ORLADEYO in its first yea
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer. In this new role, Ms. Rosselli will lead a global team to leverage and build the company’s data science, analytics and insights infrastructure, helping inform strategic decision making at BioCryst. In her new role, Ms. Rosselli will join the BioCryst leadership team and report directly to Jon Stoneho
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $84.92 per unit.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts, including one Distinguished Industry Oral Abstract, on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place in New Orleans, Louisiana, and online, from
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]